Referred to the House Committee on Ways and Means.
The bill creates a new federal income tax credit equal to 50% of qualified infertility treatment expenses for eligible individuals.
The credit is subject to a dollar cap tied to an existing Code provision, an AGI-based phaseout, and a refundable component limited to $5,000 (indexed for inflation).
The statute defines qualified infertility treatment expenses, allows pre‑treatment fertility preservation when a physician determines a future medical treatment may cause infertility, disallows double benefits when insurance or public programs reimburse expenses, and permits a five‑year carryforward of unused credits.
Content-wise the bill is a relatively narrow, administrable tax credit with built-in limits and anti-double-dipping safeguards that improve negotiability. Still, it creates a new tax expenditure with a refundable component and requires politically difficult decisions about offsets and budgetary priorities. It is more likely to succeed if attached to a broader tax/healthcare package or if cost estimates and offsets are provided; as a standalone measure the path is uncertain, especially in the Senate.
Relative to its intended legislative type, this bill is a focused substantive amendment to the Internal Revenue Code creating a tax credit for infertility treatment expenses. It provides substantial statutory detail—credit rate, definitions, limits, refundability, carryforwards, and interactions with other tax provisions—sufficient for incorporation into the Code.
Scope and inclusivity: liberals want broader eligibility (including non‑diagnosis ART users, LGBTQ and single parents); conservatives prefer narrower, medically limited coverage.
Scope and inclusivity: liberals want broader eligibility (including non‑diagnosis ART users, LGBTQ and single parents); conservatives prefer narrower, medically limited coverage.
A mainstream liberal would generally view this bill positively as a targeted federal intervention to reduce out‑of‑pocket costs for people facing infertility, and would welcome the explicit coverage for fertility preservation before iatrogenic infertility (e.g., chemotherapy).
They would likely praise the refundable portion up to $5,000 for helping lower‑ and moderate‑income families, while noting the 50% credit and five‑year carryforward as useful relief.
However, they may criticize limits and eligibility rules that could exclude some groups (for example, people seeking assisted reproduction without a formal infertility diagnosis, or anyone denied coverage because of the married‑filing requirement).
A centrist/moderate would view the bill as a targeted, market‑compatible federal subsidy to address an expensive medical cost that many insurance plans do not fully cover.
They would appreciate the credit’s structure (non‑duplication rules, partial refundability, carryforwards) but want more information on the fiscal cost and administrative implementation.
Centrists would weigh access benefits against budget impacts and potential complexity in tax administration; they would likely support the bill if it is scored and funded in a fiscally responsible way and if eligibility/verification rules are clear.
A mainstream conservative would be skeptical of creating or expanding refundable tax benefits that increase federal outlays, viewing this as an expansion of government spending into private medical decisions.
They would raise concerns about the refundable portion (direct spending), potential for fraud/administrative complexity, and whether infertility treatment subsidies are an appropriate federal role versus employer coverage or state policy.
Some conservatives might also raise ethical questions about funding certain assisted‑reproduction procedures, though the bill focuses on tax treatment rather than mandating medical practice.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise the bill is a relatively narrow, administrable tax credit with built-in limits and anti-double-dipping safeguards that improve negotiability. Still, it creates a new tax expenditure with a refundable component and requires politically difficult decisions about offsets and budgetary priorities. It is more likely to succeed if attached to a broader tax/healthcare package or if cost estimates and offsets are provided; as a standalone measure the path is uncertain, especially in the Senate.
The bill has not accumulated any surfaced votes yet.
Scope and inclusivity: liberals want broader eligibility (including non‑diagnosis ART users, LGBTQ and single parents); conservatives prefe…
Content-wise the bill is a relatively narrow, administrable tax credit with built-in limits and anti-double-dipping safeguards that improve…
Relative to its intended legislative type, this bill is a focused substantive amendment to the Internal Revenue Code creating a tax credit for infertility treatment expenses. It provides substantial statutory detail—cre…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.